# US 2003/0224520 A1 · Activation and expansion of T-cells using an engineered multivalent signaling platform

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0224520 A1
- Document ID: US20030224520A1
- Status: Published application
- Kind: A1
- Application number: 10/336,224
- Filed: 2003-01-03
- Published: 2003-12-04
- Earliest claimed: 2002-01-03
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Carl June; James Riley; Marcela Maus; Anna Thomas
- Web page: https://patentgrep.com/patent/US20030224520A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/416: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- C12N 5/0634: {Cells from the blood or the immune system}
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2502/99: genetically modified cells
- C12N 2510/00: Genetically modified cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates generally to methods for activating and expanding cells, and more particularly, to a novel method to activate and/or stimulate cells using an engineered multivalent signaling platform. Compositions of cells activated and expanded by the methods herein are further provided.

## Claims

### Claim 1

An engineered multivalent signaling platform (EMSP) for use in stimulating and/or activating T cells comprising an EMSP that expresses or displays on its surface one or more agents that ligate a cell surface moiety of at least a portion of T-cells and stimulates said T-cells.

### Claim 2 (depends on 1)

The EMSP of claim 1 wherein said platform comprises a human cell line.

### Claim 3 (depends on 2)

The EMSP of claim 2 wherein said human cell line is selected from the group consisting of K562, U937, 721.221, T2, and C1R cells.

### Claim 4 (depends on 3)

The EMSP of claim 3 wherein said human cell line is K562.

### Claim 5 (depends on 1)

The EMSP of claim 1 wherein said EMSP is a cell that is genetically modified to express a human Fcγ receptor.

### Claim 6 (depends on 5)

The EMSP of claim 5 wherein said human Fcγ receptor comprises CD32.

### Claim 7 (depends on 1)

The EMSP of claim 1 wherein said EMSP is a cell that is genetically modified to express CD32 and said one or more agent is an antibody that binds to a cell surface molecule on the surface of T cells.

### Claim 8 (depends on 7)

The EMSP of claim 7 wherein said EMSP is further genetically modified to express a co-stimulatory molecule.

### Claim 9 (depends on 8)

The EMSP of claim 8 wherein said co-stimulatory molecule is selected from the group consisting of CD80, CD86, 4-1BBL, OX40L, ICOS-L, ICAM, PD-L1 and PD-L2.

### Claim 10 (depends on 7)

The EMSP of claim 7 wherein said one or more agent is an antibody that is displayed on the surface of said EMSP via interaction with the Fcγ receptor.

### Claim 11 (depends on 7)

The EMSP of claim 7 wherein said one or more agent is a natural ligand for a cell surface molecule on the surface of a T cell.

### Claim 12 (depends on 11)

The EMSP of claim 11 wherein said natural ligand comprises the natural ligand for CD28.

### Claim 13 (depends on 11)

The EMSP of claim 11 wherein said natural ligand comprises 4-1BBL.

### Claim 14 (depends on 1)

The EMSP of claim 1 wherein said EMSP is a cell that has been modified to express a cytokine.

### Claim 15 (depends on 14)

The EMSP of claim 14 wherein said cytokine is selected from the group consisting of IL-2, GM-CSF, IL-4, TNF-α, and IFN-γ.

### Claim 16 (depends on 1)

The EMSP of claim 1 wherein said T cells comprise CD4+ T cells.

### Claim 17 (depends on 1)

The EMSP of claim 1 wherein said T cells comprise CD8+ T cells.

### Claim 18 (depends on 1)

The EMSP of claim 1 wherein said T cells comprise regulatory T cells.

### Claim 19 (depends on 10)

The EMSP of claim 10 wherein said antibody is an anti-CD28 antibody.

### Claim 20 (depends on 10)

The EMSP of claim 10 wherein said antibody is an anti-CD3 antibody.

### Claim 21 (depends on 10)

The EMSP of claim 10 wherein said antibody comprises anti-CD3 and anti-CD28.

### Claim 22 (depends on 1)

The EMSP of claim 1 wherein said one or more agent comprises at least an antigen.

### Claim 23 (depends on 22)

The EMSP of claim 22 wherein said antigen is selected from the group consisting of a tumor antigen, a bacterial antigen, a fungal antigen, a viral antigen, and an autoantigen.

### Claim 24

A method for activating or stimulating a population of T-cells by cell surface moiety ligation, comprising:
a. providing a population of cells wherein at least a portion thereof comprises T-cells;
b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein said EMSP comprises a cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein said cell is a human cell.

### Claim 27 (depends on 26)

The method of claim 26, wherein said cell is a human cell line.

### Claim 28 (depends on 24)

The method of claim 24, further comprising expanding said T-cells by incubating in the presence of EMSP.

### Claim 29 (depends on 24)

The method of claim 24, further comprising separating said T-cells from said EMSP and subsequently incubating said T-cells with an agent that facilitates T-cell expansion.

### Claim 30 (depends on 24, 25, 26, 27, 28)

The method of any one of claims 24-28, wherein the T-cell is a T-cell line.

### Claim 31 (depends on 24, 25, 26, 27, 28)

The method of any one of claims 24-28, wherein said T-cell is a T-cell clone.

### Claim 32

A method for maintaining T-cell repertoire comprising providing a population of cells having T-cells present therein, exposing said T-cells to an EMSP for a time sufficient to induce activation and subsequently expanding said T-cells.

### Claim 33 (depends on 32)

The method of claim 32, wherein said expansion occurs in the absence of said EMSP.

### Claim 34 (depends on 32)

The method of claim 32, wherein said expansion occurs in the presence of said EMSP.

### Claim 35

A method for maintaining the viability of T-cells during culture, comprising contacting said T-cells with EMSP.

### Claim 36 (depends on 35)

The method of claim 35, wherein said T-cells are CD4+ T-cells.

### Claim 37 (depends on 35)

The method of claim 35, wherein said T-cells are CD8+ T-cells.

### Claim 38 (depends on 37)

The method of claim 37, wherein said contacting occurs by sequential stimulation of T-cells by an EMSP.

### Claim 39 (depends on 38)

The method of claim 38, wherein the viability of said T-cells is greater than 50% after at least one, two, three, four, five, six, seven, or eight rounds of stimulation.

### Claim 40 (depends on 38)

The method of claim 38, wherein the viability of said T-cells is greater than 60% after at least one, two, three, four, five, six, seven, or eight rounds of stimulation.

### Claim 41 (depends on 38)

The method of claim 38, wherein the viability of said T-cells is greater than 70% after at least one, two, three, four, five, six, seven, or eight rounds of stimulation.

### Claim 42 (depends on 38)

The method of claim 38, wherein the viability of said T-cells is greater than 80% after at least one, two, three, four, five, six, seven, or eight rounds of stimulation.

### Claim 43

A method for decreasing apoptosis of a population of CD8+ T-cells, comprising stimulating said cells with EMSP, said EMSP having on its surface at least one primary stimulatory agent and at least one co-stimulatory agent.

### Claim 44 (depends on 43)

The method of claim 43, wherein said CD8+ T-cells are expanded in the presence of said EMSP.

### Claim 45 (depends on 43)

The method of claim 43, wherein said CD8+ T-cells are expanded in the absence of said EMSP.

### Claim 46 (depends on 43)

The method of claim 43, wherein said CD8+ T-cells demonstrate an increase in Bcl-XL levels compared to CD8+ T-cells expanded in the absence of initial stimulation with said EMSP.

### Claim 47 (depends on 43, 44, 45, 46)

The method of any one of claims 43-46, wherein at least one co-stimulatory agent comprises 4-1BB ligand.

### Claim 48 (depends on 47)

The method of claim 47, wherein the primary stimulatory agent comprises an agent that binds CD3.

### Claim 49 (depends on 48)

The method of claim 48, wherein said EMSP further comprises a second co-stimulatory agent that binds CD28.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 43-49, further comprising at least one sequential round of restimulation.

### Claim 51

A method for expanding a population of T-cells by cell surface moiety ligation, comprising:
a. providing a population of cells wherein at least a portion thereof comprises T-cells;
b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells; and
c. culturing said T-cells under conditions and time sufficient to induce cell division, wherein said contacting and/or said culturing occurs in the absence of exogenously added cytokines.

### Claim 52 (depends on 51)

The method of claim 51, wherein said EMSP comprises a cell.

### Claim 53 (depends on 51)

The method of claim 51, wherein said cell is a human cell.

### Claim 54 (depends on 53)

The method of claim 53, wherein said cell is a human cell line.

### Claim 55 (depends on 51)

The method of claim 51, further comprising sequentially stimulating said T-cells with EMSP either by previously purifying T-cells from originally added EMSP and subsequently adding additional EMSP or by adding additional EMSP to previously stimulated cells without separation of originally added EMSP.

### Claim 56 (depends on 51)

The method of claim 51, further comprising separating said T-cells from said EMSP and subsequently incubating said T-cells with an agent that facilitates T-cell expansion, followed by restimulation with EMSP.

### Claim 57 (depends on 51, 52, 53, 54, 55, 56)

The method of any one of claims 51-56, wherein the T-cell is a T-cell line.

### Claim 58 (depends on 51, 52, 53, 54, 55, 56)

The method of any one of claims 51-56, wherein said T-cell is a T-cell clone.

### Claim 59 (depends on 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 51-58, wherein said EMSP comprises a cell displaying a ligand for any one of CD3, CD28, or 4-1BB.

### Claim 60

A method for expanding a population of T-cells by cell surface moiety ligation, comprising:
a. providing a population of cells wherein at least a portion thereof comprises T-cells;
b. contacting said population of cells with an EMSP, said EMSP having on its surface one or more agents that ligate a cell surface moiety of at least a portion of said T-cells and activates or stimulates said T-cells; and
c. culturing said T-cells under conditions and time sufficient to induce cell division.

### Claim 61 (depends on 60)

The method of claim 60, wherein said EMSP comprises a cell.

### Claim 62 (depends on 60)

The method of claim 60, wherein said cell is a human cell.

### Claim 63 (depends on 62)

The method of claim 62, wherein said cell is a human cell line.

### Claim 64 (depends on 60)

The method of claim 60, further comprising sequentially stimulating said T-cells with EMSP either by previously purifying T-cells from originally added EMSP and subsequently adding additional EMSP or by adding additional EMSP to previously stimulated cells without separation of originally added EMSP.

### Claim 65 (depends on 60)

The method of claim 60, further comprising separating said T-cells from said EMSP and subsequently incubating said T-cells with an agent that facilitates T-cell expansion, followed by restimulation with EMSP.

### Claim 66 (depends on 60, 61, 62, 63, 64, 65)

The method of any one of claims 60-65, wherein the T-cell is a T-cell line.

### Claim 67 (depends on 60, 61, 62, 63, 64, 65)

The method of any one of claims 60-65, wherein said T-cell is a T-cell clone.

### Claim 68 (depends on 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 60-67, wherein said EMSP comprises a cell displaying a ligand for any one of CD3, CD28, or 4-1BB.

### Claim 69 (depends on 60)

The method of claim 60, wherein following initial stimulation or activation said T-cells are separated from EMSP and then expanded in the presence of exogenously added cytokines.

### Claim 70 (depends on 69)

The method of claim 69, wherein said T-cells are substantially free of EMSP prior to expansion.

### Claim 71 (depends on 51, 60)

A population of T-cells expanded by the method of claim 51 or 60, wherein said T-cells are substantially free of EMSP.

### Claim 72

A method of immunotherapy comprising administering an EMSP to a subject in need thereof, thereby stimulating a population of T-cells within the subject to expand.

### Claim 73

A method of enhancing reactivity to an antigen comprising administering an EMSP to a subject in need thereof concurrently, prior to or following inoculation of the subject with an antigen of interest, thereby stimulating a population of antigen specific T-cells within the subject to expand.

### Claim 74

A method for breaking immune tolerance comprising administering an EMSP to a subject either systemically or locally at a site of interest.

### Claim 75

A method for increasing uptake of an exogenously added nucleic acid molecule in T-cells, comprising contacting said T-cells with an EMSP and contacting said T-cells with said nucleic acid molecule thereby, said contacting of EMSP with said T-cells rendering cells more amenable to uptake of nucleic acid.

### Claim 76 (depends on 75)

The method of claim 75, wherein said exogenously added nucleic acid is operably linked to a promoter

### Claim 77 (depends on 76)

The method of claim 76, wherein said nucleic acid molecule provides gene replacement for abnormal gene product.

### Claim 78 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 24-70 wherein the natural functionality of said T-cells is preserved following stimulation and expansion

### Claim 79

A method of activating antigen specific T-cells, comprising contacting a population of T-cells an antigen and an EMSP under conditions and for time sufficient to induce activation of T-cells specific to said antigen.

### Claim 80 (depends on 79)

The method of claim 79, wherein said activation occurs ex vivo after which the T-cells are administered to a patient substantially free or in combination with said EMSP.

### Claim 81 (depends on 79)

The method of claim 79, wherein said antigen is displayed by said EMSP.

### Claim 82 (depends on 81)

The method of claim 81, wherein said display is by way of a fusion protein.

### Claim 83 (depends on 79)

The method of claim 79, wherein said antigen is in the form of a complex with MHC derived peptides.

### Claim 84 (depends on 29)

The method of claim 29, wherein said agent that facilitates T-cell expansion comprises IL-2.
